Neutropenia in Medical Technology
Navigation Links
Neutropenia in Medical Technology
... (NCI Grades 3/4) lab abnormalities-including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... included anemia (17%), thrombocytopenia (17%), neutropenia (8%), and increased creatinine (8%).
In ... abnormalities (400 mg/day; 600 mg/day)--including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia ...
... toxicities and infections, including: - neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile neutropenia reported in 7% versus 6% of patients - ... neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in ...
... (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), ... toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced ... respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral ...
... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). ... (NCI Grades 3/4) lab abnormalities -- including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ( ...
... (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), ... most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced ... were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral ...
... and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and Grade 3 or 4 platelet ... 9.5% of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ... equal to age 70, 7% and 5.5% experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ...
... (NCI Grades 3/4) lab abnormalities -- including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%) and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%) and elevated lipase (17%). ...
... CHOP-R related toxicities included grade 3 to 4 neutropenia occurred in 23 (39%) patients and grade 3 to 4 ... with Zevalin was myelosuppression. Grade 3 to 4 neutropenia occurred in 28 (51%) of patients with one incidence of febrile neutropenia requiring hospitalization. Grade 3 to 4 ...
... (NCI Grades 3/4) lab abnormalities--including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... included anemia (17%), thrombocytopenia (17%), neutropenia (8%) and increased creatinine (8%). In GIST, ... abnormalities (400 mg/day; 600 mg/day)--including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia ...
... The most commonly reported adverse events were neutropenia and mouth sores. "These preliminary results are ... Grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen. Among 11 patients evaluated ... arm, grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen. About breast cancer Breast cancer ...
... than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 ... Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. ... occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients ...
... cisplatin and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. ... in the Taxotere-based regimen included febrile neutropenia (5.2%) and neutropenic infection (13.9%). The ... Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), ...
... most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
... most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
... reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included neutropenia and asthenia. "These study results illustrate that this complex ...
... Leukine data highlights include the following: Chemotherapy-Induced neutropenia Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia Lead investigator: M. Duh, Analysis Group, Inc., Boston, MA ...
... With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 ...
... by the investigator to be unrelated to ITMN-191. The other two were neutropenia and indirect bilirubin elevation. neutropenia occurred with a similar pattern, frequency and severity in the placebo and ...
... fatigue (50 percent), diarrhea (27 percent), nausea, anorexia, and neutropenia (all 23 percent), vomiting and dizziness (18 percent). The most common Grade 3/4 toxicity was neutropenia (23 percent) and was the only Grade 3/4 adverse event that occurred in ...
... (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal ... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ...
... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ... than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... 3-5 adverse events, regardless of relation to treatment, were febrile neutropenia in 8 patients, and neutropenia and thrombocytopenia in 7 patients respectively. One patient died within ...
... pill and could theoretically reduce its effectiveness. -- Severe neutropenia [absolute neutrophil count (ANC) cardiac, and up to 3.6% of ... Patients receiving CellCept should be monitored for neutropenia. If neutropenia develops (ANC dosing with CellCept should be interrupted or the dose ...
... pill and could theoretically reduce its effectiveness. -- Severe neutropenia [absolute neutrophil count (ANC) 10cubed/microL] developed in up to ... Patients receiving CellCept should be monitored for neutropenia. If neutropenia develops (ANC CellCept should be interrupted or the dose reduced, ...
... Oncology, Hospital Saint Antoine, Paris, France. In the MOSAIC trial, neutropenia (decrease in the number of white blood cells) was the most frequently reported side effect, affecting 78.9% of patients. neutropenia was complicated by fever or infection in only 1.8% of cases. Peripheral ...
... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
... trials to have a higher risk of developing myelosuppression. Grade 3/4 neutropenia (lab and AE combined) occurred in eight percent and Grade 3/4 ... treated with temozolomide. In refractory anaplastic astrocytoma, Grade 3/4 neutropenia occurred in 14 percent and Grade 3/4 thrombocytopenia occurred in 19 ...
... and fluorouracil (PF). Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% ...
... Anaemia, leucopenia, thrombocytopenia, neutropenia. Common: Febrile neutropenia and infection without neutropenia. Uncommon: Pancytopenia. ... associated with an increased incidence of infections. Fatigue and febrile neutropenia also occur more frequently with this combination. Administration site ...
... None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was ...
... Had a Dose Reduction 2 3% 21 14% ---------------------- --- --- --- --- neutropenia (ANC less than 1500) 0 0% 3 2% -------------------------------- --- --- --- --- Diarrhea, ...
... a child while receiving treatment with Dacogen and for two months afterwards. The most commonly occurring adverse reactions with Dacogen include neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 ...
... was well tolerated. The most commonly reported adverse events (grade 3 or 4; >10% patients) in this heavily pretreated population included anemia, neutropenia and thrombocytopenia(1). About non-Hodgkin's lymphoma and Hodgkin's disease Non-Hodgkin's lymphoma and Hodgkin's disease manifest in the ...
... regimens produced encouragingly high rates of overall response (58-74%) including high rates of complete responses (37-57%). As previously reported, neutropenia was the dose limiting toxicity when used as a single agent. "In both preclinical and early clinical studies pixantrone exhibited lower cardiac ...
... toxicities and infections, including: - neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile neutropenia reported in 7% versus 6% of patients - ... neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in ...
... (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), ... toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced ... respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral ...
... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). ... (NCI Grades 3/4) lab abnormalities -- including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ( ...
... (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), ... most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced ... were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral ...
... and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and Grade 3 or 4 platelet ... 9.5% of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ... equal to age 70, 7% and 5.5% experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, ...
... (NCI Grades 3/4) lab abnormalities -- including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%) and hyperglycemia ... adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%) and elevated lipase (17%). ...
... CHOP-R related toxicities included grade 3 to 4 neutropenia occurred in 23 (39%) patients and grade 3 to 4 ... with Zevalin was myelosuppression. Grade 3 to 4 neutropenia occurred in 28 (51%) of patients with one incidence of febrile neutropenia requiring hospitalization. Grade 3 to 4 ...
... (NCI Grades 3/4) lab abnormalities--including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... included anemia (17%), thrombocytopenia (17%), neutropenia (8%) and increased creatinine (8%). In GIST, ... abnormalities (400 mg/day; 600 mg/day)--including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia ...
... The most commonly reported adverse events were neutropenia and mouth sores. "These preliminary results are ... Grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen. Among 11 patients evaluated ... arm, grade 2 and 3 mouth sores and grade 3 and 4 neutropenia were seen. About breast cancer Breast cancer ...
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in ... or hemorrhage -- Sepsis occurring during neutropenia has resulted in discontinuation of ... DOXIL vs VELCADE, respectively) included: neutropenia (36% vs 22%), thrombocytopenia (33% vs ...... than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 ... Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. ... occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients ...
Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
... met the safety criterion for duration of neutropenia (less than or equal to five days of severe neutropenia). In these trial conditions, severe neutropenia typically lasts approximately seven days ... $4 billion in 2006. About Neutropenia neutropenia is a severe decrease in neutrophil cell counts in ...Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in ... or hemorrhage -- Sepsis occurring during neutropenia has resulted in discontinuation of ... plus DOXIL vs VELCADE, respectively) included: neutropenia (36% vs 22%), thrombocytopenia (33% vs 28%), ...... cisplatin and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. ... in the Taxotere-based regimen included febrile neutropenia (5.2%) and neutropenic infection (13.9%). The ... Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), ...
... most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
... most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
... reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included neutropenia and asthenia. "These study results illustrate that this complex ...
... Leukine data highlights include the following: Chemotherapy-Induced neutropenia Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia Lead investigator: M. Duh, Analysis Group, Inc., Boston, MA ...
... With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 ...
... by the investigator to be unrelated to ITMN-191. The other two were neutropenia and indirect bilirubin elevation. neutropenia occurred with a similar pattern, frequency and severity in the placebo and ...
... fatigue (50 percent), diarrhea (27 percent), nausea, anorexia, and neutropenia (all 23 percent), vomiting and dizziness (18 percent). The most common Grade 3/4 toxicity was neutropenia (23 percent) and was the only Grade 3/4 adverse event that occurred in ...
... (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal ... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ...
... with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ... than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) ...
... 3-5 adverse events, regardless of relation to treatment, were febrile neutropenia in 8 patients, and neutropenia and thrombocytopenia in 7 patients respectively. One patient died within ...
... pill and could theoretically reduce its effectiveness. -- Severe neutropenia [absolute neutrophil count (ANC) cardiac, and up to 3.6% of ... Patients receiving CellCept should be monitored for neutropenia. If neutropenia develops (ANC dosing with CellCept should be interrupted or the dose ...
... pill and could theoretically reduce its effectiveness. -- Severe neutropenia [absolute neutrophil count (ANC) 10cubed/microL] developed in up to ... Patients receiving CellCept should be monitored for neutropenia. If neutropenia develops (ANC CellCept should be interrupted or the dose reduced, ...
... Oncology, Hospital Saint Antoine, Paris, France. In the MOSAIC trial, neutropenia (decrease in the number of white blood cells) was the most frequently reported side effect, affecting 78.9% of patients. neutropenia was complicated by fever or infection in only 1.8% of cases. Peripheral ...
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
... for the European market. The market launch is planned for early 2010. neutropenia - a condition whereby the concentration of neutrophils (a type of white ... colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the ...... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
... or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with ... hypokalemia (31.3%). Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed ...
... trials to have a higher risk of developing myelosuppression. Grade 3/4 neutropenia (lab and AE combined) occurred in eight percent and Grade 3/4 ... treated with temozolomide. In refractory anaplastic astrocytoma, Grade 3/4 neutropenia occurred in 14 percent and Grade 3/4 thrombocytopenia occurred in 19 ...
... and fluorouracil (PF). Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% ...
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
... leukopenia (16%); anemia (6%); thrombocytopenia (5%); infection without neutropenia (2%); fatigue (17%); thrombosis/embolism (6%); nausea (12%); vomiting ... (72%); chest pain (38%); neuropathy/sensory (29%); infection without neutropenia (23%); and rash (17%). See complete Warnings, Precautions, Adverse ...... Anaemia, leucopenia, thrombocytopenia, neutropenia. Common: Febrile neutropenia and infection without neutropenia. Uncommon: Pancytopenia. ... associated with an increased incidence of infections. Fatigue and febrile neutropenia also occur more frequently with this combination. Administration site ...
... None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was ...
... Had a Dose Reduction 2 3% 21 14% ---------------------- --- --- --- --- neutropenia (ANC less than 1500) 0 0% 3 2% -------------------------------- --- --- --- --- Diarrhea, ...
... a child while receiving treatment with Dacogen and for two months afterwards. The most commonly occurring adverse reactions with Dacogen include neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 ...
... was well tolerated. The most commonly reported adverse events (grade 3 or 4; >10% patients) in this heavily pretreated population included anemia, neutropenia and thrombocytopenia(1). About non-Hodgkin's lymphoma and Hodgkin's disease Non-Hodgkin's lymphoma and Hodgkin's disease manifest in the ...
... regimens produced encouragingly high rates of overall response (58-74%) including high rates of complete responses (37-57%). As previously reported, neutropenia was the dose limiting toxicity when used as a single agent. "In both preclinical and early clinical studies pixantrone exhibited lower cardiac ...
Other ContentsresponsivenessresponsivenessresponsivenessresponsivenessresponsivenessrestingrestingrestingrestingrestingrestingrestingrestingenzymesenzymesenzymesenzymesenzymesenzymesenzymesenzymeslysatelysatereticulocytereticulocytemapmapmapmapmapmapmapretinaretinaretinaretinaretinaretinaretinaretrotransposonsOther TagsNIPNIPNIPImmunoassaysOther Tagsdirectly 2directly 3directly 4directly 5directly 6directly 7directly 8directly 9directly 10adults 2adults 3adults 4adults 5adults 6adults 7adults 8adults 9adults 10become 2become 3become 4become 5become 6become 7become 8become 9become 10necessarily 2necessarily 3necessarily 4necessarily 5necessarily 6necessarily 7necessarily 8necessarily 9necessarily 10fibre 2fibre 3cancerous 2cancerous 3cancerous 4cancerous 5cancerous 6cancerous 7tied 2
(Date:11/4/2009)...2009 Childhood obesity in the United States is re...urth of advertising on daytime and prime time tele...ng questions about the role television plays in ob...he Journal of Nutrition Education and Behavior e...ht be a large contributor to the problem. , Rese...
(Date:11/4/2009)...at deciphered the DNA codes, or genomes, of the fa...oined The Genome 10K Project, an international eff...nces on 10,000 species of animals for conducting c...ot be achieved. , Participating in The Genome 10...ov. 5, 2009 issue of the Journal of Heredity , ar...
(Date:11/4/2009)... Oct. 19 Spectros, developer and m...ing devices which shed light on life-threatening d...ive distribution deals for both its T-Stat® V...ed include Australia, New Zealand, The Netherland... France, Spain, Portugal, Poland, Greece, Turkey, ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 1Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 2Mayo Clinic researchers lead national trial testing new treatment for chronic severe indigestion 57531 3Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 1National new biology initiative offers potential for remarkable and far reaching benefits 9968 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 3(Date:11/9/2009)...d device control capabilities will enable system c... enhance their data security policy enforcement. ...ov. 9, 2009 -- Lumension, a global leader in endpo...eneral availability of Lumension® Device Cont...users to protect corporate data while reducing ope...
(Date:11/9/2009)...bulance company now the only worldwide operator wi...ent of Defense approval, , ...d International, the leading U.S. air ambulance co...ation from the European Aero-Medical Institute (EU...profit association of air medical professionals an...
(Date:11/9/2009)...A Bioscience International, a leader in globalizin...unced a strategic partnership with the School of M...he agreement is another in a series of collaborati... research and development institutions to enable a...lization of novel biopharmaceutical product opport...
(Date:11/9/2009)...53 women ages 18 to 68 found that lubricant use du...ibuted to higher ratings of pleasurable and satisf...recommended to women to improve the comfort of sex...tearing, yet strikingly little available data is a...d vaginal symptoms. , The study, conducted by D...
(Date:11/8/2009)...wire/ -- The American Public Health Association (A...ns in the health reform bill passed last night by ...ouse takes important steps toward universal covera...ing our health system from one that focuses on tre...le healthy," said Georges C. Benjamin, MD, FACP, F...
Breaking Medicine News(10 mins):Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 2Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 3Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 4Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2[0] Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance[0] AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation [0] HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China[0] Indiana U. at APHA: Studies about why men and women use lubricants during sex[0] APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |